Baicalin attenuates XRCC1-mediated DNA repair to enhance the sensitivity of lung cancer cells to cisplatin

References

• Mao Y, Yang D, He J, et al. Epidemiology of lung cancer. Surg Oncol Clin N Am. 2016;25(3):439–445.
   PubMed Web of Science ®Google Scholar
• Collins LG, Haines C, Perkel R, et al. Lung cancer: diagnosis and management. Am Fam Physician. 2007;75(1):56–63.
   PubMed Web of Science ®Google Scholar
• Luo J, Zhu H, Jiang H, et al. The effects of aberrant expression of LncRNA DGCR5/miR-873-5p/TUSC3 in lung cancer cell progression. Cancer Med. 2018;7(7):3331–3341.
   PubMed Web of Science ®Google Scholar
• Hoy H, Lynch T, Beck M. Surgical treatment of lung cancer. Crit Care Nurs Clin North Am. 2019;31(3):303–313
   PubMed Web of Science ®Google Scholar
• Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med (Lond). 2018;118(Suppl 2):s41–s46.
   PubMed Web of Science ®Google Scholar
• Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA. 2018;68(1):7–30.
   Google Scholar
• Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017;180:16–23.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
   PubMed Web of Science ®Google Scholar
• Sun CY, Zhang QY, Zheng GJ, et al. Phytochemicals: current strategy to sensitize cancer cells to cisplatin. Biomed Pharmacother. 2019;110:518–527.
   PubMed Web of Science ®Google Scholar
• You J, Cheng J, Yu B, et al. Baicalin, a Chinese Herbal Medicine, inhibits the proliferation and migration of human non-small cell lung carcinoma (NSCLC) cells, A549 and H1299, by activating the SIRT1/AMPK signaling pathway. Med Sci Monit. 2018;24:2126–2133.
   PubMed Web of Science ®Google Scholar
• Xu Z, Mei J, Tan Y. Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt. Int J Oncol. 2017;50(1):93–100.
   PubMed Web of Science ®Google Scholar
• Amable L, Fain J, Gavin E, et al. Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug. Oncol Rep. 2014;32(2):469–474.
   PubMed Web of Science ®Google Scholar
• London RE. The structural basis of XRCC1-mediated DNA repair. DNA Repair (Amst). 2015;30:90–103.
   PubMed Web of Science ®Google Scholar
• Hu LY, Chang CC, Huang YS, et al. SUMOylation of XRCC1 activated by poly (ADP-ribosyl)ation regulates DNA repair. Hum Mol Genet. 2018;27(13):2306–2317.
   PubMed Web of Science ®Google Scholar
• Persaud AK, Li J, Johnson JA, et al. XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. Mol Carcinog. 2019;58(12):2327–2339.
   PubMed Web of Science ®Google Scholar
• Yousafzai NA, Zhou Q, Xu W, et al. SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer. Cell Death Dis. 2019;10(5):363.
   PubMedGoogle Scholar
• Gao X, Wang J, Li M, et al. Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs. J Cell Mol Med. 2019;23(10):6797–6804.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang F, Fan L, et al. Baicalin alleviates atherosclerosis by relieving oxidative stress and inflammatory responses via inactivating the NF-κB and p38 MAPK signaling pathways. Biomed Pharmacother. 2018;97:1673–1679.
   PubMed Web of Science ®Google Scholar
• Luo J, Dong B, Wang K, et al. Baicalin inhibits biofilm formation, attenuates the quorum sensing-controlled virulence and enhances Pseudomonas aeruginosa clearance in a mouse peritoneal implant infection model. PLoS One. 2017;12(4):e0176883.
   PubMed Web of Science ®Google Scholar
• Hung CH, Wang CN, Cheng HH, et al. Baicalin ameliorates imiquimod-induced psoriasis-like inflammation in mice. Planta Med. 2018;84(15):1110–1117.
   PubMed Web of Science ®Google Scholar
• Fang J, Wang H, Zhou J, et al. Baicalin provides neuroprotection in traumatic brain injury mice model through Akt/Nrf2 pathway. Drug Des Devel Ther. 2018;12:2497–2508.
   PubMed Web of Science ®Google Scholar
• Yu Y, Pei M, Li L. Baicalin induces apoptosis in hepatic cancer cells in vitro and suppresses tumor growth in vivo. Int J Clin Exp Med. 2015;8(6):8958–8967.
   PubMed Web of Science ®Google Scholar
• Huang Q, Zhang J, Peng J, et al. Effect of baicalin on proliferation and apoptosis in pancreatic cancer cells. Am J Transl Res. 2019;11(9):5645–5654.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu H, Wang H, et al. Baicalin inhibits breast cancer development via inhibiting IkB kinase activation in vitro and in vivo. Bioscience Rep 2018;53(6):2727–2736.
   Google Scholar
• Gao C, Zhou Y, Li H, et al. Antitumor effects of baicalin on ovarian cancer cells through induction of cell apoptosis and inhibition of cell migration in vitro. Mol Med Rep. 2017;6(6):8729–8734.
   Google Scholar
• Dou J, Wang Z, Ma L, et al. Baicalein and baicalin inhibit colon cancer using two distinct fashions of apoptosis and senescence. Oncotarget. 2018;9(28):20089–20102.
   PubMedGoogle Scholar
• Diao X, Yang D, Chen Y, et al. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase. Biosci Rep. 2019;39(4):BSR20181692.
   PubMedGoogle Scholar
• Du G, Han G, Zhang S, et al. Baicalin suppresses lung carcinoma and lung metastasis by SOD mimic and HIF-1alpha inhibition. Eur J Pharmacol. 2010;630(1-3):121–130.
   PubMed Web of Science ®Google Scholar
• Dolka I, Król M, Sapierzyński R. Evaluation of apoptosis-associated protein (Bcl-2, Bax, cleaved caspase-3 and p53) expression in canine mammary tumors: an immunohistochemical and prognostic study. Res Vet Sci. 2016;105:124–133.
   PubMed Web of Science ®Google Scholar
• Bartek J, Lukas J. DNA repair: Cyclin D1 multitasks. Nature. 2011;474(7350):171–172.
   PubMed Web of Science ®Google Scholar
• Abdel-Fatah TMA, Arora A, Moseley P, et al. ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clin. 2014;2:10–17.
   PubMedGoogle Scholar
• Caldecott KW. XRCC1 protein; form and function. DNA Repair (Amst). 2019;81:102664.
   PubMed Web of Science ®Google Scholar
• Mohni KN, Thompson PS, Luzwick JW, et al. A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined ATR inhibition and cisplatin treatments. PloS One. 2015;10(5):e0125482.
   PubMed Web of Science ®Google Scholar
• Mohni KN, Kavanaugh GM, Cortez D. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res. 2014;74(10):2835–2845.
   PubMed Web of Science ®Google Scholar
• Brem R, Fernet M, Chapot B, et al. The methyl methanesulfonate induced S-phase delay in XRCC1-deficient cells requires ATM and ATR. DNA Repair (Amst). 2008;7(6):849–857.
   PubMed Web of Science ®Google Scholar
• Nissar S, Sameer AS, Rasool R, et al. DNA repair gene-XRCC1 in relation to genome instability and role in colorectal carcinogenesis. Oncol Res Treat. 2014;37(7-8):418–422.
   PubMed Web of Science ®Google Scholar
• Fan J, Wilson PF, Wong HK, et al. XRCC1 down-regulation in human cells leads to DNA-damaging agent hypersensitivity, elevated sister chromatid exchange, and reduced survival of BRCA2 mutant cells. Environ Mol Mutagen. 2007;48(6):491–500.
   PubMed Web of Science ®Google Scholar
• Tung CL, Jian YJ, Chen JC, et al. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(6):657–666.
   PubMed Web of Science ®Google Scholar